Phreesia, Inc. (NYSE:PHR - Get Free Report) CFO Balaji Gandhi sold 886 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total transaction of $23,824.54. Following the transaction, the chief financial officer directly owned 106,661 shares in the company, valued at approximately $2,868,114.29. This trade represents a 0.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.
Phreesia Stock Performance
Shares of NYSE PHR traded up $1.03 during mid-day trading on Monday, reaching $26.51. 597,110 shares of the company's stock were exchanged, compared to its average volume of 456,444. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -35.82 and a beta of 0.72. The firm has a 50-day moving average price of $26.50 and a two-hundred day moving average price of $26.41.
Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%. The business's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.05) EPS. Analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. KeyCorp lifted their target price on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Citigroup reaffirmed a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. Canaccord Genuity Group dropped their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a report on Thursday, May 29th. Truist Financial raised their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Finally, Wall Street Zen upgraded shares of Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $32.27.
View Our Latest Stock Analysis on PHR
Institutional Investors Weigh In On Phreesia
A number of hedge funds have recently made changes to their positions in the business. Proficio Capital Partners LLC acquired a new stake in shares of Phreesia in the 4th quarter valued at $377,000. Raymond James Financial Inc. bought a new stake in shares of Phreesia during the fourth quarter worth $379,000. Swiss National Bank grew its position in shares of Phreesia by 1.3% in the 4th quarter. Swiss National Bank now owns 107,900 shares of the company's stock valued at $2,715,000 after acquiring an additional 1,400 shares during the period. American Century Companies Inc. acquired a new stake in shares of Phreesia during the 4th quarter worth about $644,000. Finally, Sei Investments Co. increased its holdings in Phreesia by 8.4% in the 4th quarter. Sei Investments Co. now owns 196,815 shares of the company's stock valued at $4,952,000 after buying an additional 15,241 shares during the period. Institutional investors own 92.10% of the company's stock.
About Phreesia
(
Get Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
